Suven Life Sciences Limited — Others, 24-01-2025: Statement of deviation(s) or variation(s) under Reg. 32

Suven Life Sciences Limited has confirmed that there were no deviations or variations in the utilization of funds raised through its Rights Issue for the quarter ended December 31, 2024. A total of ₹399.80 Crore was raised, with funds fully allocated toward specified objects, including pharmaceutical research, clinical trials, and repayment of inter-corporate deposits. The remaining balance for general corporate purposes stands at ₹22.10 Crore as of December 31, 2024. This consistent adherence to fund allocation may instill confidence among investors, indicating effective management and strategic focus in capital utilization.